Streetbeat News

Stock Prices

TNON

Tenon Medical (NASDAQ:TNON) reported Q2 2024 GAAP EPS of $(1.02), beating the estimate of $(1.08). However, sales of $901K missed the $909.5K estimate. Sales increased by 21.27% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:14 pm

CTSO

CytoSorbents (NASDAQ:CTSO) reported Q2 2024 GAAP EPS of $(0.08), beating the $(0.10) estimate. Sales were $9.895M, surpassing the $9.678M estimate and showing a 5.03% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:13 pm

RVYL

RYVYL shares are trading lower following a Q2 earnings and revenue miss.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:13 pm

XOS

Xos (NASDAQ:XOS) reported Q2 2024 GAAP EPS of $(1.23), beating the estimate of $(2.08) by 40.87%. However, sales of $15.535M missed the $16.543M estimate by 6.09%. Sales increased by 226.78% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:12 pm

ZVRA

Zevra Therapeutics (NASDAQ:ZVRA) reported Q2 2024 GAAP EPS of $(0.48), missing the $(0.44) estimate, and sales of $4.449M, beating the $4.412M estimate. EPS decreased by 500% year-over-year, while sales decreased by 47.47%.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:12 pm

INTA

Intapp shares are trading higher following the company's strong Q4 earnings report and positive guidance.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:11 pm

OUST

Ouster has announced that it is on track to deliver on its long-term financial framework and reach profitability. This positive outlook is likely to impact investor sentiment favorably.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:11 pm

BRTX

BioRestorative Therapies (NASDAQ:BRTX) reported a Q2 2024 GAAP EPS of $(0.50), beating the analyst consensus estimate of $(0.55) by 9.09%.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:10 pm

NATL

NCR Atleos (NYSE:NATL) reported Q2 2024 adjusted earnings per share (EPS) of $0.81, surpassing the analyst consensus estimate of $0.69 by 17.39%. The company also reported quarterly sales of $1.08 billion, which met the analyst consensus estimate.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:09 pm

ASXC

Asensus Surgical (AMEX:ASXC) reported Q2 2024 adjusted EPS of $(0.07), missing the $(0.06) estimate, but achieved sales of $2.207M, beating the $1.231M estimate. EPS improved by 22.22% YoY, and sales increased by 104.16% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:09 pm